Banks P K, Meyer K, Brodie A M
Department of Pharmacology and Experimental Therapeutics, University of Maryland, Baltimore 21202.
Endocrinology. 1991 Sep;129(3):1295-304. doi: 10.1210/endo-129-3-1295.
Studies were performed to test the hypothesis that the rapid decline in estradiol (E2) levels on proestrus before ovulation was due to a reduction in androgen substrate for aromatase, and that this decline in androgen was regulated by an estrogen receptor-mediated mechanism. Aromatase activity, concentrations of E2, androstenedione (A), testosterone (T), and progesterone (P4) in follicular, corpora lutea, and ovarian homogenates as well as peripheral E2, A, P4, and LH were measured in cycling rats from 1400-2000 h on proestrus. These parameters were also recorded after the expected E2 surge in animals treated at 1900 h on diestrous day 2 with the antiestrogen keoxifene (20 mg/kg), with or without an ovulatory dose of PMSG at 1600 h on proestrus. In a second experiment, P-450-17 alpha-hydroxylase/C17,20-lyase (P-450(17 alpha] activity was measured in a group of control rats at 1500, 1700, and 1900 h. Aromatase activity remained unchanged, even though serum and ovarian E2 levels were reduced from peak values at 1500 h to basal values at 1800 h (P less than 0.01). Peripheral A as well as ovarian androgens (specifically follicular but not luteal) A and T were also reduced over this time period (P less than 0.01). Although total ovarian P4 remained unchanged, follicular levels rose from 1400-2000 h (P less than 0.01). These reductions in androgens and E2 levels coincided with a marked reduction in follicular P-450(17 alpha) activity. Treatment with keoxifene with or without PMSG prevented the fall in peripheral E2 and A and the increase in peripheral P4 seen in controls. Ovarian and follicular E2, A, and to a lesser extent T were also remained at values similar to those during the E2 surge. Follicular P4 was reduced by both treatments. Neither treatment had any effect on aromatase. These results indicate that the fall in peripheral and ovarian E2 levels before ovulation was due to a decline in aromatizable androgen, through an inhibition of follicular P-450(17 alpha) enzyme activity, which appears to be mediated by an estrogen receptor-regulated mechanism.
开展了多项研究,以验证以下假说:排卵前动情前期雌二醇(E2)水平的迅速下降是由于芳香化酶的雄激素底物减少,且雄激素的这种下降受雌激素受体介导机制的调控。在动情前期14:00 - 20:00对处于发情周期的大鼠,测定其卵泡、黄体和卵巢匀浆中的芳香化酶活性、E2、雄烯二酮(A)、睾酮(T)和孕酮(P4)浓度,以及外周血中的E2、A、P4和促黄体生成素(LH)。在动情周期第2天19:00用抗雌激素药物凯昔芬(20 mg/kg)处理动物,无论是否在动情前期16:00给予排卵剂量的孕马血清促性腺激素(PMSG),在预期的E2高峰过后也记录这些参数。在第二项实验中,于15:00、17:00和19:00对一组对照大鼠测定P - 450 - 17α - 羟化酶/C17,20 - 裂解酶(P - 450(17α))活性。尽管血清和卵巢E2水平从15:00的峰值降至18:00的基础值(P < 0.01),但芳香化酶活性保持不变。在此期间,外周血A以及卵巢雄激素(特别是卵泡而非黄体中的)A和T也降低(P < 0.01)。虽然卵巢总P4保持不变,但卵泡中的P4水平在14:00 - 20:00升高(P < 0.01)。雄激素和E2水平的这些降低与卵泡P - 450(17α)活性的显著降低同时出现。用凯昔芬处理,无论是否给予PMSG,均能防止对照组中出现的外周血E2和A下降以及外周血P4升高。卵巢和卵泡中的E2、A以及程度稍轻的T也维持在与E2高峰期间相似的值。两种处理均使卵泡P4降低。两种处理对芳香化酶均无影响。这些结果表明,排卵前外周血和卵巢E2水平的下降是由于可芳香化雄激素的减少,这是通过抑制卵泡P - 450(17α)酶活性实现的,而这似乎是由雌激素受体调节机制介导的。